Cabaletta Bio Inc (CABA)

Jun 07, 2026

Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases - Yahoo Finance

Jun 07, 2026

Jun 06, 2026

Jennison Associates LLC Increases Stake in Cabaletta Bio Inc - GuruFocus

Jun 06, 2026

Jun 05, 2026

Investors’ Stock Portfolio: Top 5 Penny Stocks To Buy - Insider Monkey

Jun 05, 2026

Jun 05, 2026

Prudential (NYSE: PRU) holds 24.3M shares of Cabaletta Bio (CABA), 11.4% - Stock Titan

Jun 05, 2026

Jun 04, 2026

Jennison Associates (NASDAQ: CABA) holds 24.27M shares, 11.4% - Stock Titan

Jun 04, 2026

Jun 04, 2026

Cabaletta Bio reports phase 1/2 data for autoimmune therapy - Investing.com UK

Jun 04, 2026

Jun 04, 2026

Jefferies reiterates Cabaletta Bio stock rating on autoimmune data By Investing.com - Investing.com South Africa

Jun 04, 2026

Jun 03, 2026

CABA: Cabaletta Bio Shares Positive Clinical Updates at EULAR 20 - GuruFocus

Jun 03, 2026

Jun 03, 2026

Cabaletta Bio Highlights Rese-cel Data and Pivotal Path - TipRanks

Jun 03, 2026

Jun 03, 2026

Jefferies reiterates Cabaletta Bio stock rating on autoimmune data - Investing.com

Jun 03, 2026

Jun 03, 2026

Cabaletta Bio reports phase 1/2 data for autoimmune therapy By Investing.com - Investing.com Canada

Jun 03, 2026

Jun 03, 2026

Cabaletta Bio (CABA) details strong rese-cel data and pivotal plans in myositis, SSc and lupus - Stock Titan

Jun 03, 2026

Jun 03, 2026

Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress - The Manila Times

Jun 03, 2026

Jun 01, 2026

Cabaletta Bio Shares Tick Up Ahead of June Data Investors Await - Bez Kabli

Jun 01, 2026

May 29, 2026

CABA - Finviz

May 29, 2026

May 28, 2026

Cabaletta Bio (CABA) Climbs 2.7% as Biotech Stock Tests Key Resistance Near $4.14Low Risk Entry Stocks - thelegaladvocate.com

May 28, 2026

May 27, 2026

Cabaletta Bio(CABA) Stock Options Chain | Quotes & News - Moomoo

May 27, 2026

May 27, 2026

CABA Technical Analysis | Trend, Signals & Chart Patterns | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

May 27, 2026

May 24, 2026

CABA stock on track for best day in 6 months after positive early results from cell therapy trial - MSN

May 24, 2026

May 22, 2026

Cabaletta Reports Drug-Free Responses in CAR-T Study - MyChesCo

May 22, 2026

May 22, 2026

Cabaletta Bio (CABA) upgraded to buy: Here's why - MSN

May 22, 2026

May 21, 2026

Global Business Travel Group posts upbeat Q1 results, joins Cabaletta Bio, Aura Biosciences and other big stocks moving higher on Monday - MSN

May 21, 2026

May 21, 2026

CABA Stock Price, Quote & Chart | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

May 21, 2026

May 20, 2026

Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

May 20, 2026

May 18, 2026

Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - sharewise.com

May 18, 2026

May 15, 2026

Guggenheim Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

May 15, 2026

Cabaletta Bio Inc (CABA) Stock Price, Quote, News & History - Benzinga

May 15, 2026

May 15, 2026

Cormorant Funds disclose 10.5M-share position in Cabaletta Bio (CABA) - Stock Titan

May 15, 2026

May 15, 2026

CABA Maintains Rating by Wells Fargo -- Price Target Raised to $4.00 - GuruFocus

May 15, 2026

May 15, 2026

A Quick Look at Today's Ratings for Cabaletta Bio(CABA.US), With a Forecast Between $16 to $16 - Moomoo

May 15, 2026

May 15, 2026

Morgan Stanley Maintains Cabaletta Bio(CABA.US) With Buy Rating, Cuts Target Price to $3.61 - Moomoo

May 15, 2026

May 15, 2026

Cabaletta Bio Is Maintained at Equal-Weight by Wells Fargo - Moomoo

May 15, 2026

May 15, 2026

H.C. Wainwright Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $16 - Moomoo

May 15, 2026

May 15, 2026

Key facts: Cabaletta Q1 $0.39 Adj Loss, $43.52M Net Loss; ASGCT Data - TradingView

May 15, 2026

May 14, 2026

CABA Shows Promising Results in New Clinical Data - GuruFocus

May 14, 2026

May 14, 2026

CABA: Cabaletta Bio Signs Major Supply Agreement and Reports Pro - GuruFocus

May 14, 2026

May 14, 2026

Cabaletta Bio 2026 Q1 10-Q Filing: Financials, Risk Factors, and Forward-Looking Statements - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Unveils Promising Preconditioning-Free Rese-cel CAR-T Data and Automated Manufacturing Advances at ASGCT 2026 Annual Meeting - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Reports Promising 2026 Q1 Results: Rese-cel CAR-T Therapy Advances, New Data & $150M Financing Highlighted - Minichart

May 14, 2026

May 14, 2026

Cabaletta Bio Q1 Earnings: More Positive Data Suggests CAR-T Can Work In Autoimmune (CABA) - Seeking Alpha

May 14, 2026

May 14, 2026

Cabaletta Bio Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 14, 2026

May 14, 2026

Is Cabaletta Bio (CABA) Fairly Valued After Q1 2026? EPS -$0.39 - GuruFocus

May 14, 2026

May 14, 2026

Cabaletta Bio presents data on preconditioning-free rese-cel - Investing.com UK

May 14, 2026

May 14, 2026

Cabaletta Bio presents data on preconditioning-free rese-cel By Investing.com - Investing.com Nigeria

May 14, 2026

May 14, 2026

Cabaletta Bio Reports Encouraging RESET-PV Trial Data - TipRanks

May 14, 2026

May 14, 2026

Cabaletta Bio (NASDAQ: CABA) details Q1 loss and $150M financing - Stock Titan

May 14, 2026

May 14, 2026

Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times

May 14, 2026

May 14, 2026

Cabaletta Bio Presents Preconditioning-free Clinical Data and Automated Manufacturing Translational Data for Rese-cel at ASGCT 2026 Annual Meeting - The Manila Times

May 14, 2026

May 14, 2026

Cabaletta Bio (NASDAQ: CABA) warns on going concern despite $141M cash raise - Stock Titan

May 14, 2026

May 14, 2026

Cabaletta Bio, Inc. 1Q 2026: Net loss $(43.5M), EPS $(0.39) — 10-Q Summary - TradingView

May 14, 2026

May 14, 2026

Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

May 14, 2026